Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 March 2022 | Story Dr Nitha Ramnath | Photo istock
Online news

The University of the Free State (UFS) has joined The Conversation Africa (TCA) as a funding partner.  TCA, a not-for-profit media initiative, is part of a global platform that publishes articles written by academics and researchers.  The platform’s objective is to make the knowledge produced in the academy accessible, easy to understand, and freely available to the general public. Articles are published daily on the TC-Africa website - https://theconversation.com/africa. 

The platform uses a Creative Commons republishing model. This means articles can be republished by other media on the continent and internationally, ensuring even greater reach to audiences including academics, policy makers, funders, and the general public. 

To date, more than 55 UFS researchers and academics have published with TCA, and their articles have garnered more than 1,3 million readers globally. UFS researchers and academics are encouraged to publish with The Conversation. 

As part of the partnership, TCA will run writing workshops for UFS academics and researchers who want to enhance their writing and science communication skills. Dates for these will be announced soon.

How you can publish with The Conversation Africa

• Engage with The Conversation Africa editors when they contact you directly to write about your research area and expertise. The articles are short, ± 800 to 1 000 words.

• Pitch your idea for an article directly to The Conversation Africa here   

• Register as an author, and set up a profile

• Engage with the Communication and Research offices. Every week, The Conversation Africa sends an expert request for expert authors on topical issues to the Communication and Research offices, which can identify researchers. 
- Interested researchers are put into contact with the relevant editor at The Conversation to discuss the potential article

Why should you get published on The Conversation Africa?

Benefits for researchers and academics:

• Articles on the platform help to raise the profile of academics, often leading to policy engagement with governments, businesses, industry or professional bodies, conference invitations, academic collaborations, and further media exposure. 
• In the course of writing, academics get bespoke editorial assistance from the team working in consultation with them. 
• The opportunity to take part in a hands-on science communication writing workshop.
• Readership and republication metrics for each published article.
• A global readership with up to 1,2 million readers monthly.

Benefits for Communication and Marketing and the Research office:

• Provides well-curated, ready-to-use communication material for websites and social media. 
• Helps to profile the work of the university for marketing, communication, and awareness.
• Provides media exposure to the talent pool of UFS academics and researchers. 

Benefits for and across the university:

• Shines a spotlight on the excellent research and innovation at the UFS.
• Demonstrates the UFS’ commitment to facilitating greater engagement with society and promoting interdisciplinary communications.
• Visibility for the institution and researchers nationally and globally.
• Access to institutional analytics, including detailed data on the content published by UFS researchers.

Contact The Conversation Africa:

To arrange departmental meetings and introductory sessions to The Conversation Africa team, contact: Pfungwa Nyamukachi, Strategic Partnerships and Stakeholder Relations Manager: pfungwa.nyamukachi@theconversation.com 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept